CASI Pharmaceuticals, Inc. (CASI) Issues Earnings Results

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01, Bloomberg Earnings reports.

CASI Pharmaceuticals (NASDAQ CASI) traded down 2.09% on Friday, reaching $0.92. 12,241 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $1.02 and a 200-day moving average price of $1.24. The company’s market capitalization is $55.38 million. CASI Pharmaceuticals has a 1-year low of $0.82 and a 1-year high of $1.76.

Earnings History for CASI Pharmaceuticals (NASDAQ:CASI)

Separately, Maxim Group set a $4.00 price target on shares of CASI Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, May 16th.

COPYRIGHT VIOLATION WARNING: “CASI Pharmaceuticals, Inc. (CASI) Issues Earnings Results” was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply